Answers are grounded in this paper and cite their sources.
Fibrinogen—a 340-kDa glycoprotein—plays a crucial role in blood coagulation, platelet aggregation, wound healing, and other physiological processes. A mutation in fibrinogen may lead to congenital dysfibrinogenemia, a rare disease characterized by the functional deficiency of fibrinogen. About 580 cases of abnormal fibrinogens have been reported worldwide; thereof 335 cases in the fibrinogen Aα chain [1]. To our knowledge, only five cases of abnormal fibrinogens with two mutations [2-6] and one case of two different mutations in the same family [7] have been described earlier. A 52-year-old female was examined for bleeding. Routine hemostasis screening resulted in a diagnosis of dysfibrinogenemia. Functional testing revealed prolonged fibrin polymerization, prolonged lysis of the clot, abnormal fibrin morphology, and fibrinopeptides release. Genetic analysis showed two heterozygous nonsense mutations—previously described mutation Aα Gly13Glu and a novel mutation Aα Ser314Cys. The mutation Aα Gly13Glu was found in her brother and niece, but there was no evidence in either of the mutation Aα Ser314Cys. While mutation Aα Gly13Glu is responsible for abnormal fibrinopeptide release and prolonged thrombin time, the novel mutation Aα Ser314Cys seems to affect fibrin morphology and fibrinolysis. The patient was a 52-year-old female with abnormal hemostasis screening results (Table I). The patient reported easy bruising and purpura since childhood and menorrhagia since 13. When she was 40, varices surgery with excessive bleeding was performed. The patient had three pregnancies. She lost the first fetus after artificial insemination in the third week due to excessive bleeding. She had two successful deliveries; the first one was complicated by 6 weeks of excessive bleeding, for the second delivery she was prepared by infusion of a solution of 2 mg/ml of fibrinogen in physiological buffer and there was no bleeding. Her father died after colorectal carcinoma at age 61, her mother died after trauma at age 62. The patient's mother and grandmother had reported increased bleeding tendency but they have never been genetically examined. Both of children of the patient—an 11-year-old son and a 29-year-old daughter—had decreased functional fibrinogen level and bleeding tendencies, but were unavailable for further study. Fibrin polymerization, induced by either thrombin or reptilase, was impaired; there was a prolonged lag phase and decreased final turbidity. Fibrinolysis experiments showed a prolonged lysis phase of the patient fibrin. Study of the kinetics of fibrinopeptide release revealed an abnormal release of fibrinopeptide A (fpA) as shown in Fig. 1. FpA was released from the diluted plasma at slower rate than fibrinopeptide B (fpB). The amount of released fibrinopeptide A was about half of the normal, while an almost normal amount of fpB was released. Factor XIIIa ligation of the patient's clot was found to be normal. Scanning electron microscopy (Fig. 2) showed significantly wider fibers (284 ± 24 nm) than the control (208 ± 26 nm), n = 100, P ≤ 0.05. Sequencing of exons and exon–intron junctions of FGA, FGB, and FGG genes revealed a heterozygous FGA G3447A transition (GenBank access number M64982) predicting a heterozygous Aα Gly13Glu mutation, and a heterozygous FGA A6540T transition predicting a heterozygous Aα Ser314Cys mutation. The sequence numbering refers to genomic DNA; while the amino acid numbering refers to the circulating chain. Fibrinopeptide release kinetics (a) and fibrinolysis (b). (a) A mixture of diluted plasma (1:3, v:v, TRIS buffer pH 7.4) with o-phenanthroline hydrate (0.01 M) was treated with thrombin (0.9 U/ml, final concentration). Enzymatic reactions were stopped; samples were centrifuged; and the content of fibrinopeptides was determined by RP-HPLC. Impaired fibrinopeptide release was obtained for the patient (green), her brother (red), and the healthy control (blue). (b) The polymerization and dissolution of fibrin clots generated from citrated patient's plasma (green), citrated brother's plasma (red), or citrated control plasma (blue) were studied in reaction mixtures containing 0.5 U/ml human thrombin, 0.3 μg/ml human tPA, 8 mM Ca2+, and 0.15 U/mL human plasminogen; fibrinogen concentration was adjusted to 1 g/L. The progress of the reaction was measured by absorbance at 350 nm (each curve represents the average of three measurements). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] SEM images of the patient's fibrin (a), her brother's fibrin (b), and control fibrin (c). Fibrin clots were formed in 33 μl plasma of the patient or healthy control with the addition of 1 μl human thrombin (2 NIH U/ml, final concentration) for 3 h. The patient's 59-year-old brother presented with abnormal hemostasis screening result (Table I). He had prolonged bleeding after venipuncture, mild epistaxis, and bleeding of the gums. He has three children, two daughters, and one son with functionally confirmed dysfibrinogenemia but without genetic analysis. His 34-year-old daughter presented with similar hemostasis screening result (Table I). Their fibrin polymerization and kinetics of fibrinopeptide release were impaired similarly to the patient. Fibrinolysis was normal (Fig. 1b), as was fibrin morphology (Fig. 2b). Genetic analysis revealed a heterozygous FGA G3447A transition in both brother and his daughter predicting a heterozygous Aα Gly13Glu mutation, but there was no evidence of the Aα Ser314Cys mutation. Fibrinogen Šumperk II is the first case of combined dysfibrinogenemia with mutations Aα Gly13Glu and Aα Ser314Cys. Mutation Aα Gly13Glu has already been described by several authors [7-9]; while the mutation Aα Ser314Cys is a novel mutation, which has not been described earlier. Aα Gly13 is situated in fibrinopeptide A, N-terminal part of the Aα chain [1-16]. After successful cleavage of fibrinopeptide A from either fibrinogen in solution [10] or from surface bound fibrinogen [11], polymerization knobs are uncovered and fibrin polymerization begins. Residues of Aα 6-18 fit into the thrombin active site [12]; and the precise conformation of fibrinopeptide A is necessary for the correct thrombin-mediated release of fibrinopeptide A. But this mutation did not appear to influence either fibrin structure or fibrinolysis, as described earlier [8] and as was found in the patient's relatives without mutation Aα Ser314Cys. On the other hand, the patient with both mutations had impairment of both fibrin morphology and fibrinolysis. The amino acid residues 220-610 of the Aα chain are involved in the polymerization process and promote lateral aggregation of protofibrils [13]. The lateral aggregation of Aα Ser314Cys fibrinogen was enhanced such that variant clots had wider fibers than normal clots; therefore, it suggests that the Aα Ser314Cys mutation is responsible for changes of the fibrin structure resulting in prolonged fibrinolysis. The mutation is situated in the αC-connector, a flexible tether connecting an independently folded compact αC domain to the bulk of the molecule [14]. The replacement of serine residue by cysteine residue may change the conformation of the αC-connector, and may result in new hydrogen bonds with its neighbors; however, there are no crystallographic data available to confirm this statement. Clot retraction and contraction experiments showed that retraction index of the patient's clot was 1.28 when compared with retraction index of the control clot being 1.00. The retraction index of the brother's clot was found to be 1.04. The clot retraction have a dramatic effect on the structure of fibrin and hence on fibrinolysis [15]. Since Aα 314 Ser is situated in the flexible αC-connector, it may play an important role in the αC-domain movement. In fibrinogen, two αC-domains interact with each other and with the central region while in fibrin they switch to intermolecular interaction to form αC polymers [16]. Emerging protofibril undergoes lateral contact with other fibrils, largely mediated by intermolecular αC:αC contacts, to form thicker fibers [17] and the αC regions promote lateral aggregation of protofibrils [18]. Besides their contribution to the fibrin assembly process, the αC-domains are involved in the initiation of fibrinolysis through their tPA- and plasminogen-binding sites [19]. The effectiveness of fibrinolysis results from the combination of regulated enzymatic activity and the physical properties of the fibrin scaffold [15]. The patient's clot morphology was significantly different from the control clot as shown in Fig. 2. The authors assume that the substitution of Aα 314 serine to cysteine affects the mobility of the αC-connector and thus affects lateral aggregation of protofibrils and subsequent tPA-mediated lysis of the clot. Serine residue Aα 314 is also situated next to the fibrinogen MSCAMM binding site (Aα 316-328), binding Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCAMM) e.g., Clumping factor B from Staphylococcus aureus, which participates in the colonization of the nasal epithelium and is therefore a key virulence factor [20]. The patient's anamnesis did not show any abnormal infections caused by S. aureus, so the authors presume that there is no relationship between the mutation and the MSCAMM binding site. It is also of interest that the observations of mutated Cys residues may form disulfide bonds with cysteine; another mutated Aα chain within the same molecule; albumin; or with another fibrinogen molecule. Electrophoretic profiles of nonreduced fibrinogen on SDS polyacrylamide gels and plasma immunoblotting with an antibody directed against fibrinogen were normal. Thus, no abnormal circulating molecule was found within the detection limit of these assays, confirming either free sulfhydryl form or intramolecular disulfide bond. Several mutations have been described in the Aα Ser314 neighborhood [2, 21-23], mainly causing hypofibrinogenemia or afibrinogenemia. The mutation Aα Ser314Cys manifests however, as dysfibrinogenemia apparently due to similarity of the serine and cysteine residues, which is tolerated by molecular chaperons during fibrinogen assembly. In conclusion, the authors reported in this article, a case of dysfibrinogenemia in the patient bearing two heterozygous mutations in the fibrinogen Aα chain—Gly13Glu and Ser314Cys—affecting fibrin polymerization, fibrinopeptide release, fibrinolysis, and fibrin morphology. All samples were obtained in accordance with the Ethical Committee regulations of the Institute of Hematology and Blood Transfusion, Prague and with a release of informed consent. Routine coagulation tests were performed with citrated plasma samples on a STA-R coagulation analyzer (Diagnostica Stago, Asnieres sür Seine, France). The functional fibrinogen level was measured by the Clauss method [24]. Total fibrinogen level was determined by an immunoturbidimetric assay performed on a UV-2401PC spectrophotometer (Shimadzu, Kyoto, Japan) [25]. Fibrin polymerization induced by either thrombin or reptilase and fibrinolysis experiments, as obtained by the turbidimetrical method [26]. Fibrinopeptide release was measured as a function of time; and the fibrinopeptides were determined by the reversed-phase, high-performance liquid chromatography (RP-HPLC) method performed on a CGC SGX C18 column according to Suttnar et al [27]. The purified genomic DNA was amplified by polymerase chain reaction, using specific primers; and dideoxysequencing was performed with Dye Terminator Cycle Sequencing with a Quick Start kit and a CEQ 8000 genetic analysis system (Beckman Coulter, Fullerton, CA, USA). Scanning electron microscopy (SEM) was carried out on a VEGA Plus TS 5135 (Tescan, Brno, Czech Republic) scanning electron microscope [26]. Retraction index was calculated as the ratio of plasma volume after clot retraction to plasma volume after control clot retraction. Roman Kotlín*, Jiří Suttnar*, Irena Čápová*, Ingrid Hrachovinová*, Marie Urbánková , Jan Evangelista Dyr*, * Institute of Hematology and Blood Transfusion, Prague, Czech Republic, Department of Hematology, Šumperk Hospital, Šumperk, Czech Republic.
No takes yet. Share an insight, caveat, or question.
Kotlín et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: